What video, OP?
On the LEM trajectory, we wish to investigate the following study, because we are not finished with the thymus question of hyperplasia: that's where LEM comes from in the first place.
Ribas A, et al, Tremelimumab (CP-675,206) a Cytotoxic T Lymphocyte-Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer, Oncologist (2007) 12: 873-883)
We take a more form-follows-function approach regarding lymphocyte expansion molecules (LEM). In skin cancers, there is no place in the literature that we have yet found that compares the 'thymic wave' to skin cancers such as basal cell carcinoma. A preliminary excerpt will follow.
On the LEM trajectory, we wish to investigate the following study, because we are not finished with the thymus question of hyperplasia: that's where LEM comes from in the first place.
Ribas A, et al, Tremelimumab (CP-675,206) a Cytotoxic T Lymphocyte-Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer, Oncologist (2007) 12: 873-883)
We take a more form-follows-function approach regarding lymphocyte expansion molecules (LEM). In skin cancers, there is no place in the literature that we have yet found that compares the 'thymic wave' to skin cancers such as basal cell carcinoma. A preliminary excerpt will follow.